Tagrisso (osimertinib) supply for hospitals & distributors
Third-generation EGFR tyrosine kinase inhibitor · AstraZeneca
Tagrisso (osimertinib) is AstraZeneca's oral, once-daily third-generation EGFR tyrosine kinase inhibitor for EGFR-mutated non-small cell lung cancer. It is a room-temperature tablet product supplied in blister packs of 30.
Prescription-only medicine. No prices are published. Supply is to hospitals, distributors, pharmacies and physicians against a valid prescription or purchase order. This page is product information, not medical advice.
Product facts
Strengths and presentation
- 40 mg film-coated tablets, pack of 30
- 80 mg film-coated tablets, pack of 30
Approved indications (EMA / FDA label summary)
- Adjuvant treatment after complete resection of EGFR-mutated (exon 19 deletion / L858R) NSCLC
- First-line treatment of locally advanced or metastatic EGFR-mutated NSCLC, alone or with chemotherapy
- Unresectable stage III EGFR-mutated NSCLC after chemoradiation (label-dependent)
- EGFR T790M-positive NSCLC after progression on an earlier EGFR TKI
Short label summary only. Approved indications differ by country and line of therapy; the national label in the destination country governs.
Storage and cold chain
- Room-temperature product — store as stated on the carton, in the original pack
- No cold chain required; shipped in tamper-evident, temperature-protected packaging
How we supply
- Original manufacturer packs only — sourced from licensed wholesalers in Türkiye and Europe, never repackaged or relabelled.
- Batch number and expiry confirmed in writing before dispatch; every pack is traceable to its batch.
- Documents with every consignment: commercial invoice, batch / CoA information from the source, and packing list.
- Tamper-evident, temperature-protected shipping; no cold chain is required for this product.
- Named-patient and special-import support: we prepare the paperwork your hospital or importer needs for the local regulator.
Procurement notes
Tagrisso is a continuous daily therapy, so most orders are monthly packs of 30 × 80 mg tablets. For hospitals and distributors we can set up a recurring monthly supply with the same documentation set on every consignment.
Who we supply
- Hospital pharmacy and procurement departments
- Licensed pharmaceutical distributors and importers
- Oncology and haematology centres
- Treating physicians arranging named-patient supply
Markets served
United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain and Iraq. Import into each country follows that country's regulator (for example MOHAP / DoH / DHA, SFDA, MoPH, Kuwait MOH, Oman MOH, NHRA) — we work with the receiving institution's import route.
Frequently asked questions
Do you supply both Tagrisso 40 mg and 80 mg?
Yes, both strengths in packs of 30 film-coated tablets in the original AstraZeneca carton, subject to availability confirmed per enquiry.
Does Tagrisso need cold-chain transport?
No. Tagrisso is stored at room temperature as stated on the carton. It ships in tamper-evident, temperature-protected packaging.
Is the Tagrisso you supply an original manufacturer pack?
Yes. We supply Tagrisso only in the original AstraZeneca pack, sourced from licensed wholesalers in Türkiye and Europe, never repackaged or relabelled.
Which documents come with a consignment?
Commercial invoice, batch / CoA information from the source and a packing list, with batch number and expiry for every pack. Additional documents requested by your importer can be prepared.
Do you supply the UAE, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain and Iraq?
Yes — to hospitals, distributors and licensed centres in these countries, through the import or named-patient route accepted by the destination country's regulator.
How do I get a quote for Tagrisso?
Send a supply inquiry on WhatsApp with strength, quantity, country and institution. We reply with a written quote, availability and expiry; we do not publish prices on the site.
Send a supply inquiry
Tell us the product, strength, quantity, destination country and the receiving institution. We reply with availability, batch/expiry and the documentation set — and a written quote. We do not sell to the public.
Send a supply inquiryOther medicines we supply to the Gulf
- Keytruda (pembrolizumab)
- Opdivo (nivolumab)
- Enhertu (trastuzumab deruxtecan)
- Darzalex (daratumumab)
- Imfinzi (durvalumab)
- Tecentriq (atezolizumab)
- Perjeta (pertuzumab)
- Kadcyla (trastuzumab emtansine)
- Lynparza (olaparib)
- Revlimid (lenalidomide)
- Imbruvica (ibrutinib)
- Venclyxto (venetoclax)
- Xtandi (enzalutamide)
- Adcetris (brentuximab vedotin)
Sources
Reviewed by Pharmacy Remedy Pharmacovigilance & Compliance Desk · Last updated: 2026-11-04